Skip to main content

Advertisement

SpringerLink
Log in

Operative and Oncological Outcomes After D2 Versus D1 Gastrectomy of Operable Gastric Cancer: an Observational Study

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

The optimal surgery for operable gastric carcinoma is still controversial. The aim of the current study was to assess the outcomes of D2 compared with D1 gastrectomy.

Study

This observational study included 80 patients with operable gastric cancer treated by D2 gastrectomy at Alexandria University Hospital between January 2010 and January 2016. Another 68 patients treated by D1 gastrectomy during the same period were included. Both groups were compared regarding operative mortality, morbidities, tumor recurrence, and 5-year survival rates.

Results

D2 gastrectomy had a significantly higher postoperative mortality and morbidity rates compared with D1 group (19.4% and 41.9% versus 6.3% and 18.8%). Mean number of LNs retrieved was statistically increased in D2 compared with D1 group with more frequency of adequate lymphadenectomy (LN retrieved > 15). D2 gastrectomy demonstrated significant lower recurrence and cancer-specific mortality rates compared with D1 group (18.6% and 14.5% versus 34.9% and 30.8%) with no significant difference in DFS and OS rates. Spleen-saving D2 gastrectomy showed no significant difference in early postoperative mortality with significant increase in DFS and OS compared with D1 gastrectomy (78.7% and 82% versus 61.5% and 64.6%).

Conclusions

D2 gastrectomy had a lower recurrence and cancer-specific mortality rates than D1 gastrectomy but it had higher postoperative mortality and morbidity rates that resulted in no overall survival benefit of D2 compared with D1 gastrectomy. Spleen-saving D2 gastrectomy can be done safely in selected patients by expert surgeons without increased morbidity and mortality and better survival outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJH. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.

    Article  Google Scholar 

  2. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol. 2004;22:2069–77.

    Article  CAS  Google Scholar 

  3. Bonenkamp JJ, Hermans J, Sasako M, Welvaart K, Songun I, Meyer S, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.

    Article  CAS  Google Scholar 

  4. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79:1522–30.

    Article  CAS  Google Scholar 

  5. Degiuli M, Sasako M, Ponti A, et al. Survival results of a multicenter phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer. 2004;90:1727–32.

    Article  CAS  Google Scholar 

  6. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AFY, et al. Nodal dissection for patients with gastric cancer: a randomized controlled trial. Lancet Oncol. 2006;7:309–15.

    Article  CAS  Google Scholar 

  7. Kodera Y, Sano T. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.

    Article  Google Scholar 

  8. Bunt TM, Bonenkamp HJ, Hermans J, et al. Factors influencing noncompliance and contamination in a randomized trial of ‘Western’ (D1) versus ‘Japanese’ (D2) type surgery in gastric cancer. Cancer. 1994;73:1544–51.

    Article  CAS  Google Scholar 

  9. Clavien PA, Barkun J, Dindo D, et al. The Clavien-Dindo classification of surgical complications five-year experience. Ann Surg. 2009;250(2):187–96.

    Article  Google Scholar 

  10. Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745.

    PubMed  PubMed Central  Google Scholar 

  11. Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile? J Am Coll Surg. 2001;192:25–37.

    Article  CAS  Google Scholar 

  12. Kunizaki C, Akiyama H, Nomura M, et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol. 2006;12:7–15.

    Google Scholar 

  13. Degiuli M, Sasako M, Ponti A. Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643–9.

    Article  CAS  Google Scholar 

  14. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93:559–63.

    Article  CAS  Google Scholar 

  15. Biffi R, Chiappa A, Luca F, et al. Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: low morbidity and mortality rates in a single center series of 250 patients. J Surg Oncol. 2006;93:394–400.

    Article  Google Scholar 

  16. Degiuli M, Sasako M, Calgaro M, Garino M, Rebecchi F, Mineccia M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. Eur J Surg Oncol. 2004;30:303–8.

    Article  CAS  Google Scholar 

  17. Furukawa H, Hiratsuka M, Ishikawa O, Ikeda M, Imamura H, Masutani S, et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. Ann Surg Oncol. 2000;7:669–73.

    Article  CAS  Google Scholar 

  18. Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol. 2007;14:1312–9.

    Article  Google Scholar 

  19. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14:317–28.

    Article  Google Scholar 

  20. Kwon SJ. Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. J Gastric Cancer. 2011;11:78–85.

    Article  Google Scholar 

  21. Putchakayala K, Difronzo LA. D2 lymph node dissection improves staging in patients with gastric adenocarcinoma. Am Surg. 2011;77:1326–9.

    Article  Google Scholar 

  22. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer seminar. Lancet. 2009;374:477–90.

    Article  Google Scholar 

  23. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Alexandria Faculty of Medicine, Alexandria, Egypt

    Mohamed M. Elmessiry, Tarek A. El-Fayoumi, Haytham M. Fayed & Ahmed A. Gebaly

  2. Department of Internal Medicine, Alexandria Faculty of Medicine, Alexandria, Egypt

    Eman A. E. Mohamed

Authors
  1. Mohamed M. Elmessiry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarek A. El-Fayoumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haytham M. Fayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed A. Gebaly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eman A. E. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed M. Elmessiry.

Ethics declarations

This study was approved by Alexandria Faculty of Medicine medical ethics committee (no. 0302764) and registered in ClinicalTrial.gov (NCT04429841).

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elmessiry, M.M., El-Fayoumi, T.A., Fayed, H.M. et al. Operative and Oncological Outcomes After D2 Versus D1 Gastrectomy of Operable Gastric Cancer: an Observational Study. J Gastrointest Canc 53, 91–98 (2022). https://doi.org/10.1007/s12029-020-00548-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00548-z

Keywords

Search

Navigation